| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary targets of 2'-Deoxy-2'-fluorocytidine are not biological, as it is a synthetic intermediate. However, when incorporated into oligonucleotides, it targets specific mRNA sequences for gene silencing. The 2'-fluoro modification enhances the pharmacokinetic properties of the oligonucleotide by increasing its resistance to nucleases and improving its binding affinity.
|
|---|---|
| ln Vitro |
The antiviral properties of 2'-Deoxy-2'-fluorocytidine have been demonstrated by 50% effective concentrations (EC50) against CCHFV and CCHFV/ZsG in Huh7 cells, respectively, of 61 nM and 31 nM. Furthermore, in Huh7 cells, it demonstrates a 50% cytotoxicity concentration (CC50) of >50.0 μM[1].
In vitro, the compound is used in solid-phase oligonucleotide synthesis. It is not tested for biological activity on its own. Oligonucleotides containing this modified nucleoside have shown increased thermal stability and nuclease resistance, leading to improved efficacy in cellular assays for gene knockdown. |
| ln Vivo |
In vivo, the building block itself is not administered. The final oligonucleotides containing this modification have been studied in animal models and clinical trials for various diseases. The 2'-fluoro modification contributes to improved bioavailability and prolonged half-life of the therapeutic oligonucleotides.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to this compound. Quality control involves HPLC, NMR, and mass spectrometry to confirm purity and structure. The compound is tested for solubility and reactivity in synthesis conditions.
|
| Cell Assay |
In vitro cellular assays are not performed with the building block. The final oligonucleotides are tested for gene silencing efficacy, cytotoxicity, and off-target effects. The building block's quality is assessed by its coupling efficiency in synthesis.
|
| Animal Protocol |
In vivo animal studies are conducted with the final oligonucleotides, not the building block. The building block is not intended for direct administration.
|
| ADME/Pharmacokinetics |
2'-Deoxy-2'-fluorocytidine has a molecular formula of C9H12FN3O4 and a molecular weight of 245.21. It appears as a white to off-white solid powder with a purity of ≥98%. It is soluble in water and DMSO. The compound should be stored at -20°C, protected from moisture, and is stable for long periods under dry conditions. It is intended for research use only and is not for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of this building block is not characterized, as it is a chemical intermediate. Standard laboratory safety precautions should be followed. It is not intended for clinical use.
|
| References | |
| Additional Infomation |
2'-Deoxy-2'-Fluorocytidine is a hydroxypyrimidine.
2'-Deoxy-2'-fluorocytidine (CAS 10212-20-1) is a modified nucleoside analog used as a building block for oligonucleotide synthesis. It has a molecular formula of C9H12FN3O4 and a molecular weight of 245.21. The 2'-fluoro modification improves the metabolic stability and binding affinity of oligonucleotides. It is used in the synthesis of antisense and RNAi therapeutics. It is intended for research use only and is not approved for clinical use. |
| Molecular Formula |
C9H12FN3O4
|
|---|---|
| Molecular Weight |
245.21
|
| Exact Mass |
245.081
|
| CAS # |
10212-20-1
|
| PubChem CID |
101507
|
| Appearance |
White to yellow solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
500.1±60.0 °C at 760 mmHg
|
| Melting Point |
167ºC
|
| Flash Point |
256.2±32.9 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.697
|
| LogP |
-1.26
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
386
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)F
|
| InChi Key |
NVZFZMCNALTPBY-XVFCMESISA-N
|
| InChi Code |
InChI=1S/C9H12FN3O4/c10-6-7(15)4(3-14)17-8(6)13-2-1-5(11)12-9(13)16/h1-2,4,6-8,14-15H,3H2,(H2,11,12,16)/t4-,6-,7-,8-/m1/s1
|
| Chemical Name |
4-amino-1-[(2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 5 mg/mL (20.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (407.81 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0781 mL | 20.3907 mL | 40.7814 mL | |
| 5 mM | 0.8156 mL | 4.0781 mL | 8.1563 mL | |
| 10 mM | 0.4078 mL | 2.0391 mL | 4.0781 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
